Thyrocare Technologies · NSE: THYROCARE · BSE: 539871

Q1 FY22 results · Apr–Jun 2021

Thyrocare Technologies reported revenue from operations of ₹164.65 crore (up 192.6% from Q1 FY21) and net profit of ₹55.58 crore (up 24065.2% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY22Q1 FY21YoYQ4 FY21QoQ
Revenue from operations164.6556.27+192.6%146.84+12.1%
Other income10.491.22+759.8%3.64+188.2%
Total income175.1457.49+204.6%150.48+16.4%
Profit before share of associates & JVs and tax73.812.3931x47.45+55.6%
Share of profit/(loss) of associates & JVs(0.29)(0.26)0.18
Net profit for the period55.580.23242x37.75+47.2%
EPS, basic (₹)10.510.04263x7.14+47.2%
Net margin (%)33.80.425.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY22Q1 FY21YoYQ4 FY21QoQ
Revenue from operations159.2654.40+192.8%139.16+14.4%
Other income2.671.49+79.2%2.48+7.7%
Total income161.9355.89+189.7%141.64+14.3%
Profit before tax66.926.32+958.9%47.41+41.2%
Net profit for the period48.384.42+994.6%35.34+36.9%
EPS, basic (₹)9.150.84+989.3%6.69+36.8%
Net margin (%)30.48.125.4
Consolidated
Filed with BSE
13 Aug 2021, 19:07 IST
Board meeting
12 Aug 2021
Period
01 Apr 2021 to 30 Jun 2021
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
13 Aug 2021, 19:07 IST
Board meeting
12 Aug 2021
Period
01 Apr 2021 to 30 Jun 2021
Review status
Unaudited
Source
XBRL filing on BSE